学习工作经历

2005/09–2013/06, 中山大学,临床医学八年制(本硕博连读), 博士

2013/07-2016/12，中山大学附属第六医院，肿瘤内科，住院医师

2017/01-2020/12，中山大学附属第六医院，肿瘤内科，主治医师

2021/01-2024/12，中山大学附属第六医院，肿瘤内科，副主任医师

2025/01- 至今    中山大学附属第六医院，肿瘤内科，主任医师

主要研究方向

结直肠肿瘤围手术期治疗优化，消化道肿瘤免疫治疗耐药机制研究

科研成果

1. PTEN deficiency impairs MHC-I-mediated tumour immunity via NRF2-dependent autophagy in microsatellite stable colorectal cancer. Gut, 2026, 0:1–15. doi:10.1136/gutjnl-2026-338195.

2. Neoadjuvant mFOLFOXIRI with or without cadonilimab versus mFOLFOX6 in locally advanced colorectal cancer: A randomized phase 2  trial (OPTICAL-2). Med. 2026.

3. Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years. J Clin Oncol. 2025;43(6):633-64.

4. Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer. Cell Rep Med. 2026;7(1):102534.

5. Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial. J Clin Oncol. 2024;42(25):2978-2988.

6. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterology & Hepatology. 2022;7(1):38-48

7. Neoadjuvant Mfolfoxiri With Selective Radiotherapy in Locally Advanced Rectal Cancer: Long-term Outcomes of Phase II Study and Propensity-Score Matched Comparison With Chemoradiotherapy. Dis Colon Rectum. 2023;66(7):934-945.

联系邮箱：zhangjw25@mail.sysu.edu.cn